Post-HCV therapy liver cancer risk models reduce excess screening

Liver disease researchers recently published internally validated models that estimated the risk for hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C based on the presence of cirrhosis and sustained virologic response outcome.
“These models, which are available as web-based tools, can help stratify patients according to HCC risk, and consequently, help determine an appropriate screening strategy based on a patient’s calculated risk,” George N. Ioannou, MD, from the University of Washington, and colleagues wrote. “A screening strategy

Source link

Back to top button